Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
AffiliationCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, London, UK
MetadataShow full item record
AbstractCirculating tumour DNA (ctDNA) refers to the fraction of cell-free DNA in a patient's blood that originates from a tumour. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumours have resulted in increased interest in exploiting ctDNA as a tool to facilitate earlier detection of cancer and thereby improve therapeutic outcomes by enabling early intervention. ctDNA analysis might also have utility in the adjuvant therapeutic setting by enabling the identification of patients at a high risk of disease recurrence on the basis of the detection of post-surgical minimal (or molecular) residual disease (MRD). This approach could provide the capability to adapt clinical trials in the adjuvant setting in order to optimize risk stratification, and we argue that this objective is achievable with current technologies. Herein, we evaluate contemporary next-generation sequencing (NGS) approaches to ctDNA detection with a focus on non-small-cell lung cancer. We explain the technical and analytical challenges to low-frequency mutation detection using NGS-based ctDNA profiling and evaluate the feasibility of ctDNA profiling in both screening and MRD assessment contexts.
CitationEarly stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. 2018 Nat Rev Clin Oncol
JournalNature Reviews Clinical Oncology